Wedbush Reiterates Neutral on Intellia Therapeutics, Maintains $12 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 85.3%

Neg 0% Neu 85.3% Pos 0%

Wedbush analyst David Nierengarten reiterates Intellia Therapeutics (NASDAQ:NTLA) with a Neutral and maintains $12 price target.